Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
⏸️ Investing
3 healthcare stocks going gangbusters
⏸️ Investing
Here's why you should own CSL Limited and Cochlear Limited as the Aussie dollar falls
⏸️ Investing
CSL Limited has strong lead over Commonwealth Bank of Australia in race to $100
⏸️ Investing
3 health care stocks set to post stellar returns: CSL Limited, Ramsay Health Care Limited and Cochlear Limited
⏸️ Investing
These 10 ASX blue chip stocks will benefit from a lower Australian dollar in 2015
⏸️ Investing
Three investing tips from Warren Buffett
⏸️ Investing
3 bargain basement stocks: QBE Insurance Group Ltd, Macquarie Group Ltd and Cochlear Limited
⏸️ Investing
3 blue chip healthcare stocks I'd snap up right now with $10,000
⏸️ Investing
Who else wants 5 booming healthcare stocks?
⏸️ Investing
The race to $100: Commonwealth Bank of Australia in a narrow lead
⏸️ Investing
Will Cochlear Limited keep winning from global expansion?
⏸️ Investing
3 top ASX stocks: BHP Billiton Limited, Cochlear Limited and Santos Ltd
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
